3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
2
Phase 3
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Neoplasms
4
Leukemia, B-Cell
3
Recurrence
2
Leukemia
2
Bronchiolitis Obliterans Syndrome
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Autoimmune Diseases of the Nervous System
1
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
1
Interventions
Cyclophosphamide
60
Vincristine
57
Doxorubicin
54
Rituximab
48
Prednisone
44
Etoposide
35
Radiotherapy
34
Cytarabine
26
Filgrastim
22
Methotrexate
21
Bleomycin
21
Dexamethasone
18
Peripheral Blood Stem Cell Transplantation
14
Carmustine
14
Vinblastine
13
Prednisolone
13
VAP-cyclo protocol
12
Melphalan
12
Mitoxantrone
11
Mercaptopurine
10
Leucovorin
10
Dacarbazine
9
Ifosfamide
8
Granulocyte Colony-Stimulating Factor
8
Procarbazine
7
Methylprednisolone
7
Lenalidomide
7
Gemcitabine
7
Daunorubicin
7
Cisplatin
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma
×
ofatumumab
×
Clear all
NCT01578707
2019-12-18
RESONATEâ„¢
Pharmacyclics LLC.
Phase 3
Completed
391 enrolled
14 charts